Advertisement

Hypervirulent Klebsiella pneumoniae (hypermucoviscous and aerobactin positive) infection over 6 years in the elderly in China: antimicrobial resistance patterns, molecular epidemiology and risk factor

  • Chao Liu
  • Jun GuoEmail author
Open Access
Research

Abstract

Background

The definition of hypervirulent Klebsiella pneumoniae (hvKp), traditionally regarded as hypermucoviscosity, is controversial. However, data based on both phenotype (hypermucoviscous) and genetic (aerobactin) criteria are limited.

Methods

A retrospective study was conducted in 175 geriatric patients between January 2008 and January 2014. The clinical and molecular data, including antimicrobial susceptibility testing, extended-spectrum-β-lactamase (ESBL) production, virulence gene, and multilocus sequence typing of the hvKp-group (hypermucoviscosity and aerobactin positive) were compared with those of classic K. pneumoniae (cKp) isolates.

Results

Of 175 Kp isolates, 45.7% were hvKp. In pathogenicity, K1, K2, magA, rmpA, and rmpA2 genes were strongly associated with hvKp (P < 0.01). In the hvKp group, invasive infections (P < 0.000), liver abscess (P = 0.008), abdominal infection (P = 0.002) and septic shock (P = 0.035) are significantly higher than cKp group. Patients with better nutritional status were frequently infected with hvKp. However, host inflammatory reaction is most severe in hvKp group. Patients with diabetes (odds ratio [OR] = 2.548) and digestive diseases (OR = 2.196) are more likely to be infected with hvKp. Importantly, the detection of hvKp isolates increased from January 2008 to January 2010, January 2010 to January 2012, and January 2010 to January 2014 (12, 30, and 48 isolates, respectively). Overall, 16.3% of hvKp isolates produced ESBLs and 20.0% were MDR-hvKp. Multivariate analysis implied that infection occurred in the ICU (OR = 5.826) and patients with indwelling stomach tubes (OR = 6.461) are independent risk factors for ESBL-hvKp infection.

Conclusions

HvKp, especially ESBL-hvKp and MDR-hvKp, is emerging in the elderly. It is essential to enhance clinical awareness and management of hvKp infections.

Keywords

Klebsiella pneumoniae Hypervirulent Hypermucoviscous Aerobactin The elderly Risk factor 

Introduction

Klebsiella pneumoniae (Kp) are Gram-negative bacteria that can cause various infections. There are mainly two pathotypes that pose a threat to our health: hypervirulent (hvKp) and classical (cKp). The most common subtype of the K. pneumoniae strains is classic K. pneumoniae (cKp) notorious for their resistance to common antibiotics [1, 2, 3]. An emerging subtype, termed hypervirulent K. pneumoniae (hvKp), was first described in 1986 [4]. The hvKp strains exhibit unique features compared to cKp. The hvKp strains exhibit hypermucoviscosity to cause various severe infections in immunocompetent and young healthy individuals in addition to diseased patients [5, 6, 7, 8, 9], liking pyogenic liver abscesses (PLA) [4, 10]. However, the definition of hvKp is controversial. Host, pathogen, and host–pathogen interactions should be considered comprehensively for defining hvKp. However, most published studies have focused on the bacteria alone. A previous study concluded that major histocompatibility complex (MHC) variants, eating habits, nutritional status, and gut microbiota composition are essential host factors to investigate to enhance our understanding of the hypervirulence phenomenon [11]. Moreover, some controversies exist about the relationship between the virulent and morphological phenotype (hypermucoviscosity) [12, 13]. Using in vitro and in vivo assays, various studies showed that few hypermucoviscous K. pneumonia (hmvKp) strains are associated with high virulence [12, 13]. In animal models, hypermucoviscous K. pneumonia did not cause more severe infections and a higher mortality rate than non-hypermucoviscous K. pneumonia. In vitro and in vivo experiments showed that a few (1/5) hypermucoviscous K. pneumoniae isolates had a high virulence. Thus, identifying hvKp by the string test alone is not sufficient [11, 14].

Recently, aerobactin has been regarded as a critical virulence factor for hvKp [14, 15, 16], which is often concomitant with the mucoid phenotype. Based on this finding, a multi-centre research in China first stated the clinical and molecular characteristics of hvKp (defined as aerobactin-positive) isolate [14]. The results showed that invasive infections (especially PLA), hypermucoviscosity and most of virulence factors (K1, K2, K20, rmpA) genes are highly associated with aerobactin-positive Kp. In addition, some studies have reported that iron acquisition factors and the genes encoding the hypermucoviscous phenotype are located on the same virulence plasmid, which is not frequently present in cKp strains [5, 17, 18, 19]. Therefore, aerobactin combined with hypermucoviscosity may be a defining hvKp trait. Additionally, the elderly often has various underlying diseases, poor nutritional status and atypical manifestations.

To date, no data about antimicrobial susceptibility, epidemiology and risk factor of hvKp in the elderly has been described. Thus, we conducted a comparison of hvKp (hypermucoviscous- and aerobactin-positive) and cKp considering the host nutritional status, pathogen and host–pathogen interactions.

Methods

Patients

A retrospective study was conducted on K. pneumoniae culture-positive patients diagnosed at Chinese PLA General Hospital between January 2008 and January 2014. Duplicate isolates from the same patient were excluded. The basic demographics and clinical characteristics (underlying diseases, invasive procedures, nutritional status, and survival) of patients infected by K. pneumoniae were collected. Sequential Organ Failure Assessment (SOFA) scores were evaluated within the first 24 h after admission. To further assess the host response and nutritional status between the two pathotypes, we monitored white blood cell count (WBC), percentage of neutrophils (NEU%), total protein (TP) and albumin (ALB) as biomarkers. The study was approved by the Chinese PLA General Hospital Ethics Committee and the Guidelines for Human Experimentation (PR. China) were followed throughout. The main inclusion criteria were (1) the definition of the elderly has being 65 years old or older (≥ 65 year); (2) at least one K. pneumoniae positive culture; (3) Patients with all the indicators(WBC, NEU %, TP, ALB, SOFA score) were recruited in this study when their clinical specimens were identified as Kp. The exclusion criterions were (1) insufficient clinical data (lacking one of these above indicators) or bacterial strain sample storage and (2) co-infection cases. Infections were considered to be community-acquired infections if K. pneumoniae-positive culture was obtained from a sample isolated upon admission to the study center within 24 h. Cases without these conditions were defined as nosocomial infections.

Clinical K. pneumonia isolates

These specimens were from sputum, urine, blood and drainage fluid. The standardized isolation, culture and identification were conducted in the Department of Clinical Microbiology. All strains were stored at − 80 °C. All the strains were identified by the API 20 NE system and the Vitek II system. Moreover, species identification was further confirmed by 16S rRNA gene sequencing. The definition of hvKp required that both hypermucoviscosity and aerobactin were positive. Hypermucoviscosity was confirmed by the positive string test as previously described [20].

Antimicrobial susceptibility testing and phenotypic confirmation of extended spectrum beta lactamases (ESBL)

Antimicrobial susceptibility testing was conducted using the microbroth dilution method as previously described [6]. The following antibiotic agents were included: Amikacin, Gentamicin, Ampicillin/Sulbactam, Aztreonam, Cefazolin, Cefepime, Ceftriaxone, Ceftazidime, Ciprofloxacin, Levofloxacin, Piperacillin/Tazobactam, Trimethoprim/Sulfamethoxazole, Imipenem, Meropenem and Tobramycin. The results were interpreted using the 2017 Clinical and Laboratory Standards Institute (CLSI) guidelines. ESBL was confirmed by agar dilution test using ceftazidime and cefotaxime combined with clavulanate [14]. Multidrug-resistant isolate was defined as resistant to three or more antimicrobial classes [21].

Detection of virulence-associated gene and capsular serotype-specific (cps) genes

Genomic DNA was extracted from all K. pneumoniae isolates. Polymerase Chain Reaction (PCR) for virulence-associated genes (such as rmpA, rmpA2, magA and aerobactin) were conducted as previously described [14, 22, 23]. Capsular serotype-specific genes (K1, K2, K5, K20, K54, and K57) were amplified by PCR [14, 24]. The primers used are listed in Additional file 1: Table S1.

Multilocus sequence typing

The primers and reaction conditions of seven housekeeping genes (gapA, mdh, phoE, tonB, infB, pgi, and rpoB) were utilized according to the K. pneumoniae MLST website (http://bigsdb.pasteur.fr.html) (Additional file 1: Table S1). Allelic profiling and sequence types (STs) determination were also confirmed using the above website. In addition, for further analyses the relationship among different STs, phylogenetic analysis of housekeeping genes was performed. The concatenation of the seven housekeeping genes of K. pneumonia was conducted. A dendrogram was constructed from the concatenated sequences using the neighbour-joining method (MEGA 6.05).

Statistical analysis

SPSS software (version 20.0) was used for data analysis. Measurement data were reported as the mean ± standard deviation (SD), and count data were analysed as percentages. Student’s t-tests and the Wilcoxon rank-sum tests were performed for the analysis of continuous variables. The χ2 or Fisher’s exact test was used for categorical variables. All tests were 2-tailed. The P-value < 0.05 was considered statistically significant. To determine the risk factors for hvKp, univariate logistic regression analyses were performed. All variables with a P value < 0.05 were included in the multivariate model.

Results

Patient Characteristics

Between January 2008 and January 2014, 175 cases are appropriate for this study. Aerobactin-positive and hypermucoviscous strains were defined as hvKp, which was determined by PCR and string test. Eighty of 175 (45.7%) isolates were hvKp. The distribution of the main infection types in the hospital was hospital acquired pneumonia (130, 72.3%), urinary infection (28, 16.0%), abdominal infection (24, 13.7%) and bacteraemia (9, 5.14%). Overall, 170 (97.1%) patients were males and five (2.9%) were females; the mean age was 84.84 ± 8.48 years.

Clinical characteristics (including host response and nutritional status) of hvKp infection

The basic clinical characteristics, host response and nutritional status of patients with hvKp infections are shown in Table 1. The mean age of patients infected with hvKp is significantly younger than the cKp group (83.2 ± 8.75 years vs 86.2 ± 8.04 years, P = 0.020). A significantly higher number of patients with hvKp had diabetes (76.3% versus 54.7%; P = 0.003) as their underlying diseases. Compared with the cKp group, more patients with hvKp infections presented with invasive infections (28.8% versus 6.3%; P = 0.000), liver abscess (10.0% vs 1.1%; P = 0.008), other abscesses (16.3% vs 3.2%; P = 0.035), sepsis shock (11.3% versus 3.2%; P = 0.035) and abdominal infection (22.5% vs 6.3%; P = 0.035). However, the rate of urinary infection in the hvKp group is lower (10.0% vs 21.1%, P = 0.047). In addition, stomach tube is also less common in the hvKp group (56.3% vs 74.7%, P = 0.01). With regard to the host response, both WBC (12.87 ± 4.24 vs 10.34 ± 2.95, P = 0.000) and NEU % (78.87 ± 7.60 vs 74.23 ± 7.83, P = 0.000) are higher in patients with hvKp than the cKp group. However, patients infected with hvKp are more likely to have a lower TP (65.14 ± 4.93 vs 62.96 ± 4.71, P = 0.003) and ALB (35.54 ± 2.75 vs 34.45 ± 3.44, P = 0.021). It was also noted that although the SOFA score in the hvKp group is higher (6.84 ± 2.81 vs 4.93 ± 2.59, P = 0.000), the mortality at 28 days (17.5% vs 17.9%, P = 0.946) was not significantly different between the two groups (Table 1).
Table 1

Clinical and microbiological characteristics, host response and nutritional status of hvKp

Characteristic

HvKp (80)

cKp (95)

P value

K serotype

 K1

26 (32.5%)

3 (3.2%)

0.000

 K2

11 (13.8%)

1 (1.1%)

0.001

 K5

1 (1.3%)

0 (0%)

0.276

 K20

2 (2.5%)

5 (5.3%)

0.354

 K54

2 (2.5%)

3 (3.2%)

0.795

 K57

6 (7.5%)

7 (7.4%)

0.974

 rmpA

65 (81.3%)

17 (17.9%)

0.000

 rmpA2

58 (72.5%)

19 (20.0%)

0.000

 magA

63 (78.8%)

58 (61.1%)

0.012

Basic demographics

 Age

83.2 ± 8.75

86.2 ± 8.04

0.020

 Male

77 (96.3%)

92 (96.8%)

0.837

Underlying diseases

 Pulmonary disease

73 (91.3%)

90 (94.7%)

0.363

 Diabetes

61 (76.3%)

52 (54.7%)

0.003

 Cardiovascular disease

40 (50.0%)

58 (61.1%)

0.142

 Cerebrovascular disease

9 (11.3%)

20 (21.1%)

0.082

 Cancer

21 (26.3%)

28 (29.5%)

0.636

 Surgery within 1 mo

6 (7.5%)

11 (11.6%)

0.364

 Digestive disease

25 (31.3%)

20 (21.1%)

0.124

Catheter

 Central intravenous catheter

50 (62.5%)

65 (68.4%)

0.411

 Urinary catheter

57 (71.3%)

79 (83.2%)

0.059

 Tracheal catheter

24 (30.0%)

33 (34.7%)

0.505

 Stomach tube

45 (56.3%)

71 (74.7%)

0.01

 Drainage tube

4 (5.0%)

1 (1.1%)

0.119

Infection type

 HAP

62 (77.5%)

68 (71.6%)

0.372

 Urinary infection

8 (10.0%)

20 (21.1%)

0.047

 Invasive infection

23 (28.8%)

6 (6.3%)

0.000

  Bacteraemia

5 (6.3%)

4 (4.2%)

0.543

  Liver abscess

8 (10.0%)

1 (1.1%)

0.008

  Other abscess

13 (16.3%)

3 (3.2%)

0.003

 Abdominal infection

18 (22.5%)

6 (6.3%)

0.002

 Sepsis

41 (51.3%)

40 (42.1%)

0.227

 Septic shock

9 (11.3%)

3 (3.2%)

0.035

Host response

 WBC

12.87 ± 4.24

10.34 ± 2.95

0.000

 NEU%

78.87 ± 7.60

74.23 ± 7.83

0.000

Nutrition status

 TP

65.14 ± 4.93

62.96 ± 4.71

0.003

 ALB

35.54 ± 2.75

34.45 ± 3.44

0.021

SOFA score

6.84 ± 2.81

4.93 ± 2.59

0.000

Infection occurred in ICU

13 (16.3%)

14 (14.7%)

0.783

Relapse

5 (6.3%)

5 (5.3%)

0.779

Mortality at 28 days

14 (17.5%)

17 (17.9%)

0.946

Underline values indicate statistical significance

TP total protein, ALB albumin; HAP hospital acquired pneumonia, WBC white blood cell count, ESBLs extended spectrum beta lactamases, NEU% percentage of neutrophils

Genetic characteristics of hvKp vs cKp

Previous reports showed that the virulence-associated genes rmpA, rmpA2, magA and (K1, K2, K5, K20, K54, and K57) genes for capsular K antigens are associated with hvKp [25, 26, 27]. All isolated strains were tested for the above genes by PCR. K1, K2, rmpA, rmpA2 and magA were highly associated with hvKp (P = 0.000, 0.001, 0.000, 0.000, and 0.012, respectively). However, K5, K20, K54, and K57 were not associated with hvKp (P = 0.276, 0.354, 0.795, and 0.974, respectively). There is no strain in cKp group with K5 (Table 1).

Antimicrobial resistance and prevalence of ESBL genes among K. pneumoniae isolates

The resistance rate of almost all antibiotic agents for cKp was significantly higher than that of the hvKp group, with the exception of ampicillin, imipenem, and meropenem (Additional file 1: Table S2). All hvKp strains were resistant to ampicillin. Two hvKp isolates were resistant to carbapenems. Among hvKp strains, 16 strains (20.0%) were identified as multi-drug resistant bacteria (MDR). Fifty-one strains were identified as ESBL-producing, which was more common in the cKp group (40.0% vs 16.3%, P = 0.001). In the hvKp group, 16.3% (13/80) samples were ESBL-producing isolates, and 2 of them presented with carbapenems resistance. The detailed information about the 13 ESBL-producing hvKp strains is shown in Table 2.
Table 2

Clinical and microbiological characteristics of ESBL-producing hvKp isolates

Clinical characteristic

P14

P32

P34

P45

P51

P65

P92

P133

P145

P212

P221

P233

P237

Age

 

86

73

89

90

94

79

85

86

93

91

93

86

Gender

M

M

M

M

M

M

M

M

M

M

M

M

M

Clinical department

Cardiology

ICU

Urology

CCU

Respiratory

ICU

Endocrinology

Respiratory

Gastroenterology

ICU

Cardiology

Respiratory

CCU

Date of specimen (yr/mo/day)

2011/04/18

2010/10/10

2010/07/14

2008/10/24

2008/07/22

2010/10/14

2011/08/11

2011/07/11

2013/05/19

2014/01/21

2013/05/15

2013/09/11

2013/01/16

Main underlying diseases

Cardiovascular diseases

UIP

Prostate Disease

CHD

Bronchiectasis

Diabetes

Diabetes

UIP

Diabetes

UIP

Heart failure

Diabetes

Diabetes

Tube

CVC; ureter; stomach tube

CVC; ureter; stomach tube; tracheal catheter

CVC; ureter; stomach tube; tracheal catheter

CVC; ureter; stomach tube

Ureter; stomach tube

CVC; ureter; stomach tube; Tracheal catheter

CVC; ureter; stomach tube; tracheal catheter

Non

Non

CVC; ureter; stomach tube; tracheal catheter

CVC; ureter; stomach tube

Stomach tube

Stomach tube

Specimen type

Sputum

Sputum

Urine

Urine

Sputum

Sputum

Sputum

Sputum

Sputum

Sputum + blood

Urine

Sputum

Sputum

Infection type

Pneumonia

Sepsis

Sepsis

Urinary infection

Pneumonia

Sepsis

Sepsis

Pneumonia

Pneumonia

Sepsis shock

Urinary infection

Pneumonia

Pneumonia

WBC (109/L)

14.36

11.35

13.14

7.33

8.34

7.38

13.2

8.47

12.26

14.1

8.3

9.45

13.3

NEU (%)

82.9

87.6

81.3

69.2

67.5

66.3

83.1

70.5

78.3

64.4

69.3

81.3

76.3

TP (g/L)

67

63.7

75

61

58

60

61

69

68

61

64

62

67

ALB (g/L)

35.2

30.7

35.7

34.5

31.3

31.5

32.9

39

36.9

32.6

37.2

36.5

37.8

MDR

Y

Y

Y

Y

Y

Y

Y

N

N

Y

Y

Y

N

Antibiotic resistance type

Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones

Penicillins; cephalosporins; aminoglycosides

Penicillins; cephalosporins; sulfonamides

Penicillins; cephalosporins; aminoglycosides

Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones; Sulfonamides

Penicillins; cephalosporins; aminoglycosides; beta-lactamase inhibitor; quinolones; Sulfonamides

Penicillins; cephalosporins; quinolones

Penicillins; cephalosporins;

Penicillins; cephalosporins

Penicillins; cephalosporins; aminoglycosides

Penicillins; cephalosporins; aminoglycosides

Penicillins; cephalosporins; sulfonamides

Penicillins; cephalosporins

Empiric Therapy

CIP + CAZ

MEM + ISE

CMZ

IPM

MXF

CIP + CAZ

IPM + ISE

MXF

MXF

TZP + ISE

MXF

CIP + CAZ

CIP + CAZ

Switched Therapy

MEM

MEM

MXF

TZP

MEM

CAZ + TZP

IPM

MXF

MXF

MEM + CIP

MXF

CIP + ISE

CIP + ISE

SOFA score

6

7

10

3

5

7

8

3

5

11

5

7

6

Clinical outcome

Survived

Survived

Survived

Survived

Survived

Survived

Survived

Survived

Survived

Died

Survived

Survived

Survived

String test length (mm)

100

30

50

100

40

20

200

45

20

60

8

8

50

Virulence-associated genes

             

rmpA

+

+

+

+

+

+

+

+

rmpA2

+

+

+

+

+

+

+

magA

+

+

+

+

+

+

+

+

+

+

+

+

aerobactin

+

+

+

+

+

+

+

+

+

+

+

+

+

cps genes

             

K1

+

+

K2

K5

K20

K54

K57

+

MLST genotyping

2899

2892

34

2888

1264

412

2898

2920

23

17

2836

101

23

Clone complex

Singleton

CC292

CC34

CC1

CC11

CC412

CC1

singleton

CC23

CC17

CC292

CC101

CC23

M male, ICU intensive care unit, CCU coronary care unit, UIP usual interstitial pneumonia, CHD coronary heart disease, CVC central venous catheter, CIP ciprofloxacin, MEM meropenem, IPM imipenem, TZP piperacillin tazobactam, ISE isepamicin, CMZ cefmetazole, MXF moxifloxacin, CAZ ceftazidime, Y yes, N no

The distribution time and the rate of multi-drug resistance of hvKp were investigated. During the periods from January 2008 to January 2010, February 2010 to January 2012, February 2012 to January 2014, 12, 30, and 48 hvKp isolates were detected, respectively. At the three time points, 2, 6, and 5 ESBL-hvKp strains and 2, 8, and 6 MDR-hvKp strains were detected, respectively. Furthermore, an increase in the number of ESBL-hvKp isolates was detected during the periods from January 2008 to January 2010 (n = 2), February 2010 to January 2012 (n = 6), and February 2012 to January 2014 (n = 5). Additionally, 2, 8 and 6 MDR-hvKp stains were observed in the above three time points, respectively (Fig. 1).
Fig. 1

Number of hypervirulent Klebsiella pneumoniae (hvKp), ESBL-hvKp and MDR-hvKp strains detected between January 2008 and January 2014. (black, hvKp; red, ESBL-hvKp; blue, MDR-hvKp)

Risk factors: hvKp vs cKp

In this study, univariate regression analysis showed that diabetes (odds ratio [OR] = 2.655) and digestive diseases (OR = 2.152) were statistically significant risk factors associated with hvKp infections (Table 2). Indwelling stomach tube (OR = 0.435) is a protective factor for hvKp infection. Moreover, multivariate analysis revealed that diabetes (OR = 2.548) and digestive diseases (OR = 2.196) were independent risk factors for hvKp infections (Table 3).
Table 3

Risk factor for hvKp vs cKp

Variable

Univariate OR (95% CI)

P value

Multivariate OR (95% CI)

P value

Infection occurred in ICU

1.123 (0.494–2.552)

0.783

  

Pulmonary diseases

0.579 (0.177–1.901)

0.368

  

Diabetes

2.655 (1.380–5.108)

0.003

2.548 (1.288–5.042)

0.007

Cardiovascular disease

0.638 (0.349–1.164)

0.143

  

Cerebrovascular disease

0.475 (0.203–1.113)

0.087

  

Cancer

0.852 (0.438–1.657)

0.636

  

Surgery within 1 mo

0.619 (0.218–1.756)

0.368

  

Digestive diseases

2.152 (1.033–4.483)

0.041

2.196 (1.003–4.806)

0.049

Central intravenous catheter

0.769 (0.411–1.439)

0.411

  

Urinary catheter

0.502 (0.244–1.035)

0.062

  

Tracheal catheter

0.805 (0.425–1.524)

0.506

  

Stomach tube

0.435 (0.229–0.824)

0.011

  

Italic values indicate statistical significance

Risk factors: ESBL-hvKp vs Non-ESBL-hvKp

Patients infected in the ICU department (OR = 5.826) and indwelling stomach tube (OR = 6.421) are significant independent risk factors for ESBL-producing hvKp infections by regression analysis (Table 4).
Table 4

Risk factor for ESBL-hvKp vs Non-ESBL-hvKp

Variable

Univariate OR (95% CI)

P value

Multivariate OR (95% CI)

P value

Infection occurred in ICU

4.609 (1.208–17.591)

0.025

5.826 (1.334–25.446)

0.019

Stomach tube

5.338 (1.099–25.941)

0.038

6.461 (1.218–34.259)

0.028

Relapse

3.879 (0.58025.936)

0.162

  

Pulmonary diseases

1.180 (0.13010.713)

0.883

  

Diabetes

1.046 (0.2564.271)

0.950

  

Cardiovascular disease

2.613 (0.1399.322)

0.732

  

Cerebrovascular disease

1.558 (0.2858.513)

0.609

  

Cancer

0.196 (0.0241.609)

0.129

  

Digestive diseases

0.705 (0.1752.837)

0.623

  

Central intravenous catheter

0.952 (0.2813.233)

0.938

  

Urinary catheter

0.891 (0.2453.242)

0.861

  

Tracheal catheter

1.579 (0.458–5.441)

0.469

  

Italic values indicate statistical significance

MLST genotypic analysis

Among the 175 K. pneumoniae isolates, 119 STs were identified by MLST analysis, including 37 novel STs (ST2868–2869, ST2871–2878, ST2882–2884, ST2887–2892, ST2894–2901, ST2905–2906, ST2908–2909, ST2911, ST2914, ST2916–2918, ST2920). The most prevalent ST in this study was ST23 (n = 22;18.5%), followed by ST37 (n = 6;5.0%), ST11 (n = 5;4.2%), and ST412 (n = 5;4.2%). These 4 STs accounted for 27.7% (33/119) of the total strains. Moreover, 97 isolates identified another 97 distinct STs. ST23, ST412, ST218, ST375, and ST65 were strongly associated with hvKp, while ST11, ST37, and ST461 were more common in the cKp group. The most common clone complex (CC) of the ESBL-hvKp strains were CC1 (N = 2), CC23 (N = 2) and C292 (N = 2), followed by CC412, CC101, CC17, CC34, CC11 and two singletons. The phylogenetic tree showed that the ST347 isolate produced a serious infection (SOFA = 8), and the other STs (ST595, ST2906, ST1469) resulted in death (Fig. 2).
Fig. 2

Neighbour-joining dendrogram of concatenated sequences of seven housekeeping genes from the MLST database

Discussion

To our knowledge, our study is the first systematic study of hvKp defined as hypermucoviscosity and aerobactin positive and provides a comprehensive assessment of this definition regarding the host nutritional status, pathogen and host–pathogen interactions in the elderly. In the present study, nearly half of K. pneumonia (45.7%) accounted for infection in the elderly. Additionally, it is noted that, in the elderly, the detection of hvKp among the K. pneumoniae isolates increased from 2008 to 2014, indicating an elevated risk for hvKp infection, which is consisted with a previous study focusing on adults in China [20]. In our study, 45.7% of K. pneumonia were identified as hypermucoviscous through a positive string test, which is higher than a previous retrospective study conducted at a single centre in China, with a prevalence of 33% in Beijing [20]. HvKp is emerging in the elderly and may be a potential “superbug” for further clinical practice. However, the hypermucoviscous phenotype may not the unique key trait of hvKp. Moreover, patients with WBC, NEU%, TB, ALB can be included into this study. Therefore, the prevalence of hvKp in the elderly may be incorrectly estimated due to the lack of objective diagnostic methods and small sample size.

The resistance rate to common antibiotics (except carbapenems) in hvKp strains was still significantly lower than that in the cKp group in this study, particularly with regard to ESBLs. In addition, 16.3% of ESBL production was found among hvKp strains in our study, which is higher than previous article [14]. It is widely recognized that carbapenemase-producing hvKp (CR-hvKp) strains have cause various fatal infections, especially an outbreak in critical patients [17, 28, 29]. It was confirmed that the carbapenemase-producing plasmid could be successfully transferred into hvKp strains, leading to a large burden of disease for the public health [30]. In this study, MDR-hvKp is increasing and 2 hvKp isolates show high resistant to carbapenems in the elderly. It is alarming that CR-hvKp isolates are emerging, and it is a big challenge for medical workers to put forward new clinical intervention and prevention. Taken together, these data revealed that antimicrobial resistance is increasing among hvKp strains, which is consisted with a previous study [20]. However, the conclusion requires further investigation at multi-centres with a larger cohort of individuals to be confirmed. Moreover, the results show that the ESBL-hvKp is highly associated with magA in the study. The genetic characteristics and outer genetic environment of the two genes need to be further studied by whole genomic sequencing.

With regard to virulence factors, various types of K-antigens have been reported by now [24, 31, 32]. The most important elements are K1 and K2, which frequently result in serious infection [33, 34]. In our study, K1 and K2 are significantly higher in hvKp group than cKp group. RmpA/RmpA2 and MagA responsible for hypermucovicosity phenotype was proposed as another virulent factor in addition to cps K1/K2 [19, 23, 35, 36]. Our results showed that rmpA, rmpA2 and magA were closely related to hvKp group. These results revealed that most of the virulence factors are highly associated with this new definition of hvKp in the elderly.

Previous studies showed that hmvKp are frequently cause of invasive severe infection [37] in young people without underlying disease, such as PLA [2], suppurative endophthalmitis [38], and meningitis [39, 40]. In this study, the results show that the mean age of hvKp group is slightly younger than cKp. Invasive infection, especially liver abscess and other abscesses, occurred significantly more often with the new definition of hvKp group. In addition, the nutritional status (TP and ALB), host reaction (WBC and NEU %) and SOFA score of the hvKp group are significantly higher than cKp group. Moreover, the above results may also reveal that from the host, pathogen, and host–pathogen interactions, the new definition for hvKp may be highly associated with the real hypervirulence. Thus, focusing only on STs, serotypes, and other pathogen genomic data may not be sufficient to define hvKp. Host, pathogen and host–pathogen interactions should be taken into consideration when defining hvKp. The inflammatory factors (such as interleukin, C-reactive protein, tumour necrosis factor) and nutritional status (prealbumin, thickness of subcutaneous fat) may be more comprehensively considered in future studies.

It is essential for clinicians to respond immediately to hvKp infections, which could cause serious infections and a more severe inflammatory reaction than cKp, especially in the elderly, children and immunocompromised patients. Thus, developing a better understanding of the risk factors for hvKp is urgent and essential. Our results demonstrate that patients with diabetes and digestive diseases are more likely to be infected with hvKp, which is consistent with a previous study in China [14, 20]. Additionally, infections in the ICU and patients with indwelling stomach tube are risk factors for ESBL-hvKp, which may be related with potentially prolonged hospitalized course and antibiotic exposure. Clinicians should pay close attention to these risk factors in clinical practice to reduce emergence of MDR isolates. Previous study [28] suggested that wards previously infected with CR-hvKp should be left unoccupied for more than 2 weeks after disinfection and before the admission of new patients. However, it may be difficult to be implemented in China, a populous and developing country. Thus, it is urgent to make a cluster strategy from the host nutritional status, pathogen invasiveness and host–pathogen reaction to prevent MDR-hvKp, especially CR-hvKp.

There were some limitations in our study. First, it was a retrospective study at a single centre over 6 years. More inflammatory factors and nutrition indicators were not measured. Second, in vitro and in vivo experiments, such as galleria mellonella model, mouse models and a human neutrophil assay, may be further needed for identifying this new definition of hvKp. Third, to further explore the pathogen genomic characteristics, whole genome sequencing may be needed for further study. A prospective multi-centre study that includes more isolates, focusing on host, pathogen and host–pathogen interactions, is needed to better define the hvKp strains.

Conclusions

The hvKp strains defined as hypermucoviscous and aerobactin positive are more likely to cause more severe inflammatory reaction in host and invasive infection, such as PLA and sepsis shock. To further understand hvKp, the host, pathogen and host–pathogen interactions may be the key element. At present, the prevalence of hvKp in the elderly, especially ESBL-hvKp and MDR-hvKp is increasing. It is essential to enhance the clinical awareness and management of hvKp infections.

Notes

Authors’ contributions

JG and CL were responsible for study design, performing PCR, statistical analyses, writing and collecting clinical data. JG performed critical data review. Both authors read and approved the final manuscript.

Acknowledgements

We thank the team of curators of the Institut Pasteur MLST and whole genome MLST databases for curating the data and making them publicly available at http://bigsdb.pasteur.fr.

Competing interests

The authors declare that they have no competing interests.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Informed consent was not needed due to the retrospective nature of the study. The study was approved by the Chinese PLA General Hospital Ethics Committee, and the Guidelines for Human Experimentation (PR. China) were followed throughout.

Funding

This work was supported by the China postdoctoral science foundation (Grant Number 2014M562610) and the Excellent Young Program of the Organization Department of Beijing Municipal Party Committee (Grant Number 2016000057592G258).

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary material

12941_2018_302_MOESM1_ESM.docx (17 kb)
Additional file 1: Table S1. Primers. Table S2. Comparison of antimicrobial resistance to hvKp and cKp.

References

  1. 1.
    Gupta A. Hospital-acquired infections in the neonatal intensive care unit-Klebsiella pneumoniae. Semin Perinatol. 2002;26:340–5.CrossRefGoogle Scholar
  2. 2.
    Ko WC, Paterson DL, Sagnimeni AJ, Hansen DS, Von Gottberg A, Mohapatra S, et al. Community-acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis. 2002;8:160–6.CrossRefGoogle Scholar
  3. 3.
    Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998;11:589–603.CrossRefGoogle Scholar
  4. 4.
    Casanova C, Lorente JA, Carrillo F, Perez-Rodriguez E, Nunez N. Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med. 1989;149:1467.CrossRefGoogle Scholar
  5. 5.
    Shon AS, Bajwa RP, Russo TA. Hypervirulent (hypermucoviscous) Klebsiella pneumoniae: a new and dangerous breed. Virulence. 2013;4:107–18.CrossRefGoogle Scholar
  6. 6.
    Fang CT, Lai SY, Yi WC, Hsueh PR, Liu KL, Chang SC. Klebsiella pneumoniae genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. Clin Infect Dis. 2007;45:284–93.CrossRefGoogle Scholar
  7. 7.
    Decre D, Verdet C, Emirian A, Le Gourrierec T, Petit JC, Offenstadt G, et al. Emerging severe and fatal infections due to Klebsiella pneumoniae in two university hospitals in France. J Clin Microbiol. 2011;49:3012–4.CrossRefGoogle Scholar
  8. 8.
    Pomakova DK, Hsiao CB, Beanan JM, Olson R, MacDonald U, Keynan Y, et al. Clinical and phenotypic differences between classic and hypervirulent Klebsiella pneumonia: an emerging and under-recognized pathogenic variant. Eur J Clin Microbiol Infect Dis. 2012;31:981–9.CrossRefGoogle Scholar
  9. 9.
    Yu WL, Fung CP, Ko WC, Cheng KC, Lee CC, Chuang YC. Polymerase chain reaction analysis for detecting capsule serotypes K1 and K2 of Klebsiella pneumoniae causing abscesses of the liver and other sites. J Infect Dis. 2007;195:1235–6 (author reply 1236).CrossRefGoogle Scholar
  10. 10.
    Wang JH, Liu YC, Lee SS, Yen MY, Chen YS, Wang JH, et al. Primary liver abscess due to Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 1998;26:1434–8.CrossRefGoogle Scholar
  11. 11.
    Catalan-Najera JC, Garza-Ramos U, Barrios-Camacho H. Hypervirulence and hypermucoviscosity: two different but complementary Klebsiella spp. phenotypes? Virulence. 2017;8:1–13.CrossRefGoogle Scholar
  12. 12.
    Zhang Y, Zeng J, Liu W, Zhao F, Hu Z, Zhao C, et al. Emergence of a hypervirulent carbapenem-resistant Klebsiella pneumoniae isolate from clinical infections in China. J Infect. 2015;71:553–60.CrossRefGoogle Scholar
  13. 13.
    Lin YC, Lu MC, Tang HL, Liu HC, Chen CH, Liu KS, et al. Assessment of hypermucoviscosity as a virulence factor for experimental Klebsiella pneumoniae infections: comparative virulence analysis with hypermucoviscosity-negative strain. BMC Microbiol. 2011;11:50.CrossRefGoogle Scholar
  14. 14.
    Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, et al. High prevalence of hypervirulent Klebsiella pneumoniae infection in china: geographic distribution, clinical characteristics, and antimicrobial resistance. Antimicrob Agents Chemother. 2016;60:6115–20.CrossRefGoogle Scholar
  15. 15.
    Russo TA, Olson R, MacDonald U, Beanan J, Davidson BA. Aerobactin, but not yersiniabactin, salmochelin, or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae ex vivo and in vivo. Infect Immun. 2015;83:3325–33.CrossRefGoogle Scholar
  16. 16.
    Russo TA, Olson R, Macdonald U, Metzger D, Maltese LM, Drake EJ, et al. Aerobactin mediates virulence and accounts for increased siderophore production under iron-limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae. Infect Immun. 2014;82:2356–67.CrossRefGoogle Scholar
  17. 17.
    Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al. A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital: a molecular epidemiological study. Lancet Infect Dis. 2018;18(1):37–46.CrossRefGoogle Scholar
  18. 18.
    Struve C, Roe CC, Stegger M, Stahlhut SG, Hansen DS, Engelthaler DM, et al. Mapping the evolution of hypervirulent Klebsiella pneumoniae. MBio. 2015;6:e00630.CrossRefGoogle Scholar
  19. 19.
    Siu LK, Yeh KM, Lin JC, Fung CP, Chang FY. Klebsiella pneumoniae liver abscess: a new invasive syndrome. Lancet Infect Dis. 2012;12:881–7.CrossRefGoogle Scholar
  20. 20.
    Li W, Sun G, Yu Y, Li N, Chen M, Jin R, et al. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin Infect Dis. 2014;58:225–32.CrossRefGoogle Scholar
  21. 21.
    Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81.CrossRefGoogle Scholar
  22. 22.
    Choi MJ, Ko KS. Loss of hypermucoviscosity and increased fitness cost in colistin-resistant Klebsiella pneumoniae sequence type 23 strains. Antimicrob Agents Chemother. 2015;59:6763–73.CrossRefGoogle Scholar
  23. 23.
    Yu WL, Ko WC, Cheng KC, Lee HC, Ke DS, Lee CC, et al. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis. 2006;42:1351–8.CrossRefGoogle Scholar
  24. 24.
    Cheng NC, Yu YC, Tai HC, Hsueh PR, Chang SC, Lai SY, et al. Recent trend of necrotizing fasciitis in Taiwan: focus on monomicrobial Klebsiella pneumoniae necrotizing fasciitis. Clin Infect Dis. 2012;55:930–9.CrossRefGoogle Scholar
  25. 25.
    Jung SW, Chae HJ, Park YJ, Yu JK, Kim SY, Lee HK, et al. Microbiological and clinical characteristics of bacteraemia caused by the hypermucoviscosity phenotype of Klebsiella pneumoniae in Korea. Epidemiol Infect. 2013;141:334–40.CrossRefGoogle Scholar
  26. 26.
    Lin JC, Yeh KM, Chang FY. The distant metastasis of pyogenic liver abscess caused by Klebsiella pneumoniae serotype K2 and the underlying disease of diabetes mellitus should be carefully interpreted. Clin Infect Dis. 2007;45:1531–2 (author reply 1532–1533).CrossRefGoogle Scholar
  27. 27.
    Lin WH, Wang MC, Tseng CC, Ko WC, Wu AB, Zheng PX, et al. Clinical and microbiological characteristics of Klebsiella pneumoniae isolates causing community-acquired urinary tract infections. Infection. 2010;38:459–64.CrossRefGoogle Scholar
  28. 28.
    Zhang R, Lin D, Chan EW, Gu D, Chen GX, Chen S. Emergence of carbapenem-resistant serotype K1 hypervirulent Klebsiella pneumoniae strains in China. Antimicrob Agents Chemother. 2015;60:709–11.CrossRefGoogle Scholar
  29. 29.
    Liu Y, Li XY, Wan LG, Jiang WY, Yang JH, Li FQ. Virulence and transferability of resistance determinants in a novel Klebsiella pneumoniae sequence type 1137 in China. Microb Drug Resist. 2014;20:150–5.CrossRefGoogle Scholar
  30. 30.
    Siu LK, Huang DB, Chiang T. Plasmid transferability of KPC into a virulent K2 serotype Klebsiella pneumoniae. BMC Infect Dis. 2014;14:176.CrossRefGoogle Scholar
  31. 31.
    Pan YJ, Fang HC, Yang HC, Lin TL, Hsieh PF, Tsai FC, et al. Capsular polysaccharide synthesis regions in Klebsiella pneumoniae serotype K57 and a new capsular serotype. J Clin Microbiol. 2008;46:2231–40.CrossRefGoogle Scholar
  32. 32.
    Chuang YP, Fang CT, Lai SY, Chang SC, Wang JT. Genetic determinants of capsular serotype K1 of Klebsiella pneumoniae causing primary pyogenic liver abscess. J Infect Dis. 2006;193:645–54.CrossRefGoogle Scholar
  33. 33.
    Yeh KM, Kurup A, Siu LK, Koh YL, Fung CP, Lin JC, et al. Capsular serotype K1 or K2, rather than magA and rmpA, is a major virulence determinant for Klebsiella pneumoniae liver abscess in Singapore and Taiwan. J Clin Microbiol. 2007;45:466–71.CrossRefGoogle Scholar
  34. 34.
    Brisse S, Fevre C, Passet V, Issenhuth-Jeanjean S, Tournebize R, Diancourt L, et al. Virulent clones of Klebsiella pneumoniae: identification and evolutionary scenario based on genomic and phenotypic characterization. PLoS ONE. 2009;4:e4982.CrossRefGoogle Scholar
  35. 35.
    Yeh KM, Chang FY, Fung CP, Lin JC, Siu LK. magA is not a specific virulence gene for Klebsiella pneumoniae strains causing liver abscess but is part of the capsular polysaccharide gene cluster of K. pneumoniae serotype K1. J Med Microbiol. 2006;55:803–4.CrossRefGoogle Scholar
  36. 36.
    Fang CT, Chuang YP, Shun CT, Chang SC, Wang JT. A novel virulence gene in Klebsiella pneumoniae strains causing primary liver abscess and septic metastatic complications. J Exp Med. 2004;199:697–705.CrossRefGoogle Scholar
  37. 37.
    Liu YM, Li BB, Zhang YY, Zhang W, Shen H, Li H, et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China. Antimicrob Agents Chemother. 2014;58:5379–85.CrossRefGoogle Scholar
  38. 38.
    Abdul-Hamid A, Bailey SJ. Klebsiella pneumoniae liver abscess and endophthalmitis. BMJ Case Rep. 2013;2013:bcr2013008690.CrossRefGoogle Scholar
  39. 39.
    Tang LM, Chen ST, Hsu WC, Chen CM. Klebsiella meningitis in Taiwan: an overview. Epidemiol Infect. 1997;119:135–42.CrossRefGoogle Scholar
  40. 40.
    Chang WN, Huang CR, Lu CH, Chien CC. Adult Klebsiella pneumoniae meningitis in Taiwan: an overview. Acta Neurol Taiwan. 2012;21:87–96.PubMedGoogle Scholar

Copyright information

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of Respiratory Medicine, Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina
  2. 2.Department of Respiratory Medicine, Beijing Tsinghua Changgung Hospital, School of Clinical MedicineTsinghua UniversityBeijingChina
  3. 3.Department of Geriatric Respiratory MedicineChinese PLA General HospitalBeijingChina

Personalised recommendations